Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S095035 in MTAP-deleted Advanced Solid Tumors
2025-521249-25-00Phase 2Authorised
- Sponsor
- Servier
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of s095035 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), biliary cancer and 3 more (9 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities (DLTs) in Phase 1, Safety and tolerability in Phase 1 and 1 more. Planned start Sep 2025; status: authorised.
02
Drugs
s095035
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)biliary cancerpancreatic adenocarcinoma (PDAC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2025-521249-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521249-25-00.